Multidimensional analyses of proinsulin peptide-specific regulatory T cells induced by tolerogenic dendritic cells by Suwandi, J.S. et al.
Contents lists available at ScienceDirect
Journal of Autoimmunity
journal homepage: www.elsevier.com/locate/jautimm
Multidimensional analyses of proinsulin peptide-specific regulatory T cells
induced by tolerogenic dendritic cells
Jessica S. Suwandia,1, Sandra Labana,1, Kincsὅ Vassa, Antoinette Joostena, Vincent van Unena,2,
Boudewijn P.F. Lelieveldtb, Thomas Hölltc,d, Jaap Jan Zwagingaa,e, Tatjana Nikolica,1,
Bart O. Roepa,f,∗,1
a Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands
bDepartment of LKEB Radiology, Leiden University Medical Center, Leiden, Netherlands
c Computational Biology Center, Leiden University Medical Center, Leiden, Netherlands
d Computer Graphics and Visualization, Delft University of Technology, Delft, Netherlands
e Sanquin Research, Center for Clinical Transfusion Research and Jon J van Rood Center for Clinical Transfusion Science, Leiden University Medical Center, Leiden,
Netherlands
fDepartment of Diabetes Immunology, Diabetes & Metabolism Research Institute at the Beckman Research Institute, City of Hope, USA






A B S T R A C T
Induction of antigen-specific regulatory T cells (Tregs) in vivo is the holy grail of current immune-regulating
therapies in autoimmune diseases, such as type 1 diabetes. Tolerogenic dendritic cells (tolDCs) generated from
monocytes by a combined treatment with vitamin D and dexamethasone (marked by CD52hi and CD86lo ex-
pression) induce antigen-specific Tregs. We evaluated the phenotypes of these Tregs using high-dimensional
mass cytometry to identify a surface-based T cell signature of tolerogenic modulation. Naïve CD4+ T cells were
stimulated with tolDCs or mature inflammatory DCs pulsed with proinsulin peptide, after which the suppressive
capacity, cytokine production and phenotype of stimulated T cells were analysed. TolDCs induced suppressive T
cell lines that were dominated by a naïve phenotype (CD45RA+CCR7+). These naïve T cells, however, did not
show suppressive capacity, but were arrested in their naïve status. T cell cultures stimulated by tolDC further
contained memory-like (CD45RA-CCR7-) T cells expressing regulatory markers Lag-3, CD161 and ICOS. T cells
expressing CD25lo or CD25hi were most prominent and suppressed CD4+ proliferation, while CD25hi Tregs also
effectively supressed effector CD8+ T cells.
We conclude that tolDCs induce antigen-specific Tregs with various phenotypes. This extends our earlier
findings pointing to a functionally diverse pool of antigen-induced and specific Tregs and provides the basis for
immune-monitoring in clinical trials with tolDC.
1. Introduction
T regulatory cells (Tregs) are specialized to control auto-immune
responses and therefore vital in maintaining immune homeostasis. In
type 1 diabetes, however, loss of tolerance to β-cell antigens results in
the destruction of insulin-producing cells. Strategies to induce or in-
crease Tregs have been developed in an effort to reduce immune in-
flammation in patients with autoimmune diseases[1–5]. In an attempt
to induce islet antigen-specific Tregs, we established that dendritic cells
(DCs) treated with 1,25(OH)2 vitamin D3 (1,25-dihydrox-
ycholecalciferol; VitD3) and dexamethasone (VitD3/Dex) during their
modulation and maturation from monocytes induce antigen-specific
Tregs in vitro [6–9]. These tolerogenic DCs (tolDC) additionally show
various suitable functional traits such as islet autoantigen-dependent
inhibition of effector T cells [6], elimination of cytotoxic CD8+ T cells
[10,11] and homing characteristics to the disease lesion [8,12]. More-
over, the effect of tolDC was demonstrated in vivo using a humanized
transgenic mouse model, where proinsulin peptide-pulsed tolDCs
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prevented and reversed autoimmunity to proinsulin[13]. Therapy with
tolDCs loaded with specific antigens therefore appears a promising
approach to reduce autoimmunity and introduce antigen-specific tol-
erance in type 1 diabetes. The safety of this strategy has been tested
recently in a phase I clinical trial (https://www.trialregister.nl/trial/
5425).
One of the major challenges encountered in immunomodulating
trials is the lack of specific surface markers to determine the induction
of adaptive immune tolerance, including induction or expansion of
adaptive Tregs in vivo. Naturally occurring Tregs (nTregs) show con-
sistent expression of the intracellular transcription factor Foxp3 that is
often used as a Treg specification marker[14]. Although the role of
Foxp3 as biomarker of tolerance is evident[15,16], both adaptive Tregs,
e.g. Tr1 cells [17,18], show low or transient expression of Foxp3 similar
to activated effector T cells [19,20]. In contrast, other surface molecules
such as Lag-3, CTLA-4, PD-1, ICOS, CCR4, CD39, HLA-DR are present
on subsets of nTreg [21] as well as on adaptive Tregs [8,22] and may be
more useful for detection of induced suppressive T cells. Moreover, our
previous data on tolDC-induced Tregs pointed to a diversity of Treg
subtypes at a clonal level based on the intracellular cytokines and
suppressive mechanisms[22]. Further determining the cell surface
maker signatures of tolDC-induced Tregs may provide means for
monitoring Treg induction in human trials.
In this study, we applied mass cytometry (CyTOF) detecting 35
surface markers simultaneously. The innovative Cytosplore software
[23] enabled analyses of this high-dimensional data set with single-cell
resolution using Hierarchical Stochastic Neighbor Embedding (HSNE)
[23–25]. This novel approach enabled us to extend previous studies
with current in depth investigation of surface marker expression pat-
terns of proinsulin-specific Tregs induced by tolDCs and to correlate to
their capacity to suppress T cell proliferation.
2. Material and methods
2.1. Generation and quality control of human tolDCs and mDCs
Human peripheral blood mononuclear cells (PBMC) were isolated
with Ficoll density gradient centrifugation from HLA-typed buffy coats
purchased from Sanquin. All participants have given a written informed
consent. The protocol of generating monocyte derived mDCs and tolDCs
has been described[6]. After 48 h of activation with LPS (100 ng/mL)
and human GM-CSF (800 U/mL), matured tolDCs and mDCs were
stained for FACS analysis. Cells were washed with FACS buffer (PBS/
0.5%BSA/0.02%Azide) and stained with APC-labelled PD-L1 (clone
MIH1, Ebioscience, Cat# 17-5983-42, Lot# E12159-1634) and CD25
(clone M-A251, BD, Cat# 560987, Lot# 5176736), FITC-labelled CD52
(clone YTH34.5, Serotec AbD, Cat# MCA1642F, Lot# 0215) and PE-
labelled CD86 (clone 2331, BD, Cat# 560957, Lot# 5128592). Flow
cytometric staining was analysed on the FACS Canto II (BD) and data
analysis was performed using FlowJo V10.
2.2. Inducing TtolDC and TmDC lines from naïve CD4+ T cells
Cryopreserved immature tolDCs and control DCs were thawed and
activated for 48 h with LPS (100 ng/mL, Sigma-Aldrich Chemie) in the
presence of human GM-CSF (800 U/mL, Invitrogen). Naïve autologous
CD4+ T cells were isolated from CD14 negative fraction using un-
touched human CD4+ T cell kit (Dynal, Invitrogen) or naïve CD4+ T
cell isolation kit (MACS, Miltenyi Biotec), according to the suppliers’
protocol. To exclude the possibility that suppressive T cells expand or
arise from activated nTregs, CD25hi T cells were depleted in the isola-
tion method of naïve CD4+ T cells. Activated tolDCs or mDCs were
loaded with proinsulin peptide C19A3 for 4 h (7.5 μg/ml) and co-cul-
tured with naïve CD4+ T cells to induce antigen specific T cell lines
(TtolDC and TmDC respectively) as described previously [9].
2.3. Flow cytometry based sorting of T cells
TtolDC and TmDC lines were activated for 24 h with mDCs pulsed with
C19A3 peptide as previously described and stained for sorting. Staining
was performed on ice. Cells were washed with PBS/2%FCS and stained
with APC-Cy7-labelled CD25 (clone M-A251, BD, Cat# 557753, Lot#
64916) and AF700-labelled CD45RA (clone HI100, Biolegend, Cat#
555365, Lot# B227350) for 30min. Thereafter, cells were washed
twice and taken up in PBS/2%FCS. Finally, sorting was done on
FACSAria III (BD) and cells were collected in 50% FCS and 50% IMDM.
2.4. Suppression of allogeneic naïve CD4+ T cells
To assess capacity of TtolDC and TmDC lines to suppress proliferation
of naïve CD4+ T cells, allogeneic donors (donor A) were selected to
mismatch with the DC and T cell donors (donor B) bearing HLA-DR4
(the HLA restriction element of the proinsulin peptide C19A3), to allow
quantification of antigen-specific suppression. Naïve CD4+ T cells from
donor A were labelled with 0.5 μM/ml CFSE (per 2*106 cells/ml) and
cultured in the presence of activated and C19A3 loaded mDCs from
donor B at a 10:1 ratio in a 96 round bottom plate, coated with 0.1 μg/
ml anti-human CD3 mAb (clone UCHT1, BD). Purified naïve T cells
(control for crowding), TtolDC or TmDC cells from donor B were added at
a 1:1 ratio to the CFSE labelled responder T cells. Each condition was
tested in triplicate. After 4 days, cells were recovered and analysed on
the FACS Calibur (BD). Prior to the analysis, 10,000 Flow-Count
Fluorospheres were added (Beckman Coulter). For each sample, 5000
fluorosphere events were acquired for quantitative comparison of
samples. Division (d) of responder cells were calculated as expansion












An expansion index of 1.0 (no division) forms the 0% proliferation
value. Proliferation of CFSE labelled naïve CD4+ T cells in the presence
of naïve CD4+ T cells (crowding control) forms the 100% proliferation
value.
2.5. Suppression of cytotoxic CD8+ T cells
To assess whether TtolDC and TmDC lines suppress cytotoxic CD8+ T
cells, a cytotoxicity assay was performed using B cell line (JY) as target
cells and clonal PPI-specific CD8+ T cells as effector[10]. Target B cells
were labelled with a high dose of CFSE (1 μM/ml), representing a by-
stander target (CFSEhigh) or labelled with a low dose of CFSE (0.1 μM/
ml) and pulsed PPI peptide (5 μg/ml) to serve as a specific target
(CFSElow+PPI) of PPI-specific CD8+ T cells. CFSElow+PPI and CFSEhigh
target cells were co-cultured overnight with sorted TtolDC in 1:1:2 ratio.
During the last 4 h, PPI-specific CD8+ T cells were added in 1:1 and 1:5
(specific target: effector) ratio, after which cells were recovered and
analysed on the FACS Calibur (BD). Each condition was tested in du-
plicate. Percentage killing was calculated by using the formula:
= =
+
Lysis L x a b
a b
( ) ( )
a=CFSEhigh target cell
b=CFSElow+PPI target cell
=Inhibition L L CD
L no L no CD
% 100 (T ) (no 8)
( T ) ( 8)
100%tolDC
tolDC
Specific lysis was calculated by normalizing for spontaneous cell
death in the absence of PPI-specific CD8+ T cells. Inhibition of specific
lysis was calculated by dividing specific killing in the presence of a
TtolDC line or a sorted cell subset with specific killing with PPI-specific
CD8+ T cells added alone (100% lysis).
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2.6. Intracellular Foxp3 staining
TtolDC were stimulated overnight with C19A3-pulsed mDC and wa-
shed with FACS buffer. Cells were fixed and thereafter stained with
AF647-labelled Foxp3 (clone 259D, Beckman Coulter, Cat# B30650) in
permeabilizing reagent (PerFix-nc Kit, Beckman Coulter) for 1 h at
room temperature. Fluorescent staining was measured on the FACS
Calibur (BD).
2.7. Cytokine release assays
TtolDC and TmDC cells were stimulated for 24 h with activated mDCs
loaded with C19A3 peptide at a 10:1 ratio in a 96 round bottom plate.
Supernatant was taken and stored at −80 °C until analysis. Cytokine
analysis was done with Luminex 9-plex kit of BioRad according to the
manufacturer's protocol.
2.8. Staining TtolDC and TmDC lines for CyTOF and data acquisition
The CyTOF antibody staining panel consisted of 35 surface markers
including markers described for Tregs, lineage, differentiation and ac-
tivation (Table 1). Metal-conjugated antibodies were either purchased
or conjugated as described previously[26]. TtolDC and TmDC lines were
activated for 24 h with mDCs pulsed with C19A3 peptide and stained
for CyTOF analysis. For this, cryopreserved TtolDC and TmDC lines were
thawed, washed and stimulated overnight with C19A3 peptide loaded
mDC at a 10:1 ratio in a 96 round bottom plate. Staining was performed
the next day, as previously described[26].
2.9. Analysis of CyTOF data
Live and single cells were distinguished using DNA stains and event
length in FlowJo V10. Beads were excluded and cells were gated to be
CD4+, CD45+, TCRgd− and CD8−, and used for further analysis. PCA
analysis of samples was performed using Partek software, version 7.0
2018 (Partek Inc., St. Louis, MO, USA). Next, SPADE trees were gen-
erated in Cytobank[27] with 200 target number nodes and 10% down
sampled event target. Finally, dimensionality reduction technique
HSNE implemented in Cytosplore[25] (version 2.2.0) was used for in-
depth analysis of the dataset without down sampling. The amount of
hierarchical levels suitable for HSNE analysis was determined with the
formula log10 (n/100) and was set to 4 (n= 1,016,321 cells). Values
were Arcsine transformed and HSNE analysis was performed based on
the expression of the 35 markers listed in Table 1. Using the Gaussian-
mean-shift method subsequent clusters were generated. Heatmaps were
generated using R software (R package, version 99.902). Packages
‘flowcore’, ‘ggplot 2’, ‘gplots’ and ‘heatmap.2’ were used to assist in
clustering and heatmap drawing.
2.10. Statistics
Statistical analysis was performed with GraphPad Prism version
7.00 (GraphPad Software, La Jolla California, USA). To compare dif-
ferences in suppression and fold-expansion between TtolDC and TmDC
lines, data were compared by a two-sided Student's t-test (paired). One-
way ANOVA followed by Dunnett's multiple comparisons test was used
to compare the suppression of sorted T cell populations. Cytokine
production of TtolDC and TmDC lines was compared using Wilcoxon
matched-pairs signed-rank test, statistical significance was corrected for
multiple comparisons with the Benjamini and Hochberg procedure.
Median expression values were normalized by log 10 transformation
and subsequently analysed using multiple t-tests, statistical significance
was corrected for multiple comparisons using the Holm-Sidak method.
3. Results
3.1. TolDCs expressing low CD86 induce suppressive T cell lines
Naïve CD4+ T cells were stimulated by proinsulin peptide C19A3-
loaded autologous tolDC or matured inflammatory DCs (mDC) (the
generated T cell cultures further referred to as TtolDC and TmDC, re-
spectively). After two rounds of antigen-specific stimulation, TtolDC and
TmDC cells were tested in a suppression assay using a previously es-
tablished protocol[6,8,9,22,28]. In short, proliferation of allogeneic
CFSE labelled naïve CD4+ T cells in the presence of TtolDC or TmDC and
C19A3-pulsed mDC (10:10:1 ratio TCFSE: TtolDC/TmDC: DC) was mea-
sured after 4 days of co-culturing. The proliferation of CFSE-labelled
responder T cells was suppressed in the presence of TtolDC cells whereas
enhanced in the presence of TmDC cells, compared to the proliferation in
the presence of purified naïve T cells as crowding control (paired t-test;
p= 0.04; Fig. 1A). Two out of eight TtolDC lines showed no suppressive
activity (Fig. 1A), which was associated with the inability to induce
tolDCs expressing low levels of CD86 (Fig. 1D). This is in line with our
previous report where low CD86 expression was important to char-
acterize tolerogenic modulation of DCs [6,29]. Indeed, other char-
acteristics of these two non-suppressive TtolDC lines were also discordant
with suppressive TtolDC. In the suppressive TtolDC lines, the yield was
similar to the number of naïve T cells at the start of culture, whereas the
cell number in the two non-suppressive TtolDC lines increased 3 and 8
fold compared to the start (Fig. 1B). The yield of T cells stimulated by
mDCs was on average 12-fold higher after culture (paired t-test;
p= 0.003) (Fig. 1B). The production of IL-5, IL-10, IL-13, IFN-g and
TNF-a was evaluated after re-stimulation with C19A3-pulsed mDCs.
Suppressive TtolDC lines produced significantly lower amounts of IL-5,
IL-10, IL-13 and TNFa as compared to their TmDC counterparts
Table 1
Staining panel for mass cytometry.
Marker Metal Clone Dilution
CD3 170Er UCHT1 1:100
CD4 145Nd RPA-T4 1:200
CD7 153Eu CD7-6B7 1:100
CD8a 146Nd RPA-T8 1:50
CD16 148Nd 3G8 1:100
CD20a 163Dy 2H7 1:200
CD25 149Sm 2A3 1:100
CD27 167Er O323 1:100
CD28a 171 Yb CD28.2 1:100
CD38 172 Yb HIT2 1:200
CD39a 162Dy A1 1:100
CD45 89Y HI30 1:100
CD45RA 169 Tm HI100 1:100
CD45ROa 173 Yb UCHL1 1:100
CD49ba 176 Yb P1e6c5 1:100
CD69 144Nd FN50 1:50
CD103a 155Gd Ber-ACT8 1:50
CD107 (LAMP)a 143Nd H4A3 1:50
CD122a 158Gd TU27 1:50
CD126 (IL6R)a 154Sm UV4 1:40
CD127 165Ho AO19D5 1:200
CD152 (CTLA4)a 166Er 14D3 1:40
CD161 164Dy HP-3G10 1:100
CD194 (CCR4) 156Gd L291H4 1:100
CD196 (CCR6) 141Pr G034E3 1:100
CD197 (CCR7) 159 Tb G043H7 1:100
CD223 (Lag-3) 150Nd 874501 1:40
CD278 (ICOS) 151Eu DX29 1:50
CD279 (PD-1) 175Lu EH 12.2H7 1:100
CD335 (NKp46)a 174 Yb 9E2 1:50
CD336 (Nkp44)a 147Sm P44-8 1:50
CD357 (GITR)a 142Nd 621 1:40
HLA-DRa 168Er L243 1:200
KLRG-1a 160Gd REA261 1:50
TCRgd 152Sm 11F2 1:50
a Self-conjugated.
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(Wilcoxon signed-rank test; p= 0.019 for all cytokines; Fig. 1C),
whereas this trend was not observed in non-suppressive TtolDC lines.
Altogether, T cells stimulated with tolDCs or mDCs showed a dichotomy
in suppressive capacity and cytokine production, while tolDCs expres-
sing high CD86 induced non-suppressive T cells similar to mDC sti-
mulated cultures.
3.2. High-dimensional phenotype analysis of TtolDC and TmDC lines with
mass cytometry
To extensively characterize the surface phenotype of the suppressive
T cells induced by tolDCs, we employed CyTOF technology to analyse
five independently generated TtolDC lines and corresponding TmDC lines,
of which one was a non-suppressive TtolDC line. The median expression
(caption on next page)
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of the 35 tested surface molecules was evaluated, revealing differential
expression patterns between TtolDC and TmDC lines (Fig. 2A). TtolDC lines
showed higher expression of CD27 and CD45RA than TmDC (multiple t-
tests; p= 0.049 and p < 0.0001, respectively). The expression of
CCR4, CD45RO, CD39, CD38 and CD25 was lower in TtolDC than in
TmDC lines (multiple t-tests; p= 0.049, p=0.03, p < 0.0001,
p=0.009 and p=0.01, respectively). The phenotype of the non-sup-
pressive TtolDC line differed from the suppressive TtolDC lines, as well as
from TmDC lines. We further performed principal component analysis
(PCA) to cluster the generated T cell lines, integrating the median ex-
pression patterns of all markers simultaneously (Fig. 2B). The TtolDC and
TmDC lines clustered separately, while the non-suppressive TtolDC line
Fig. 1. TolDC phenotype correlates with the capacity to induce suppressive T cells. A) The suppressive capacity of TtolDC and TmDC. mDCs pulsed with C19A3
were co-cultured with CFSE-labelled allogeneic naïve CD4+ T cells in the presence of TtolDC or TmDC (ratio 1:10:10). Proliferation was calculated based on the
expansion index (EI) and the grey bar depicts the proliferation in presence of naïve CD4+ T cells (crowding control). TtolDC inhibited the proliferation of naïve CD4+
T cells, whereas TmDC stimulated the proliferation of naïve CD4+ T cells, n= 8 per group (paired t-test; p= 0.045). Two TtolDC lines (blue symbols) did not suppress
proliferation of responder CD4+ T cells, compared to the autologous TmDC line. B) Fold expansion of T cells in culture. T cells stimulated with mDC expanded on
average 12-fold, whereas tolDC -stimulated T cells did not increase in number after two weeks co-culture, n=12 per group (paired t-test p= 0.003). The two non-
suppressive TtolDC lines did expand 3-fold and 8- fold in culture. Picture inserts show T cells after 5 days of co-culture with tolDC (green frame) or mDC (red frame). C)
Cytokine production by TtolDC and TmDC during overnight stimulation with proinsulin peptide-pulsed mDC. TmDC lines produced significantly more IL-5, IL-10, IL-13
and TNF-a than suppressive TtolDC lines, n= 7 per group (Wilcoxon signed rank test; p= 0.019 for all four cytokines). Non-suppressive TtolDC were not included in
the statistical analysis. D) Left panel shows representative phenotype of tolDCs (green) and mDCs (red) used to stimulate T cells determined by CD86 and CD52
expression. Right panel shows the phenotype of tolDCs used to induce the non-suppressive TtolDC line (blue). (For interpretation of the references to colour in this
figure legend, the reader is referred to the Web version of this article.)
Fig. 2. TtolDC and TmDC lines show distinct phenotypes. T cell lines were stimulated overnight with proinsulin-pulsed mDC and labelled with a CyTOF antibody
panel. The green symbols depict suppressive TtolDC, red symbols depict TmDC and blue symbol shows the phenotype of the non-suppressive TtolDC line. A) Log10
transformed median expression of TtolDC and TmDC, the whiskers visualise the range minimum to maximum. The lines show different expression of CD27, CD45RA,
CCR4, CD45RO, CD39, CD38 and CD25, TtolDC n=4 and TmDC n=5 (multiple t-tests; p= 0.049, p < 0.0001, p= 0.049, p= 0.025, p < 0.0001, p= 0.009 and
p= 0.01). The non-suppressive TtolDC was not included in the statistical analysis. B) Principal Component Analysis of TtolDC and TmDC lines based on the median
expression of 35 immune markers. The non-suppressive TtolDC line included in the analyses clusters close to the TmDC lines and separately from the suppressive TtolDC
lines. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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clustered within the TmDC lines. These results demonstrate differences
in surface phenotypes of T cell lines induced by tolDCs versus mDCs.
Next, we analysed the TtolDC and TmDC lines using the SPADE al-
gorithm[30] and visualised these individually to explore the variability
between and within TtolDC and TmDC lines. In the SPADE analysis, the
multidimensional data set is down sampled and clustered into a two-
dimensional tree such that cells with a similar phenotype cluster into a
node, where the node branch is based on the differences in the marker
expression pattern between clusters (Fig. 3). Overall, TtolDC lines
showed different cluster distributions compared to TmDC lines, although
variation in cluster size was detectable within the TtolDC or TmDC lines.
Moreover, the non-suppressive TtolDC line lacked a group of clusters that
were present in the other suppressive TtolDC lines (Fig. 3, grey arrow).
To evaluate the phenotype of these clusters, we visualised the marker
expressions as a colour overlay (Supplementary Fig. 1). Clusters specific
to the suppressive TtolDC lines only were CD45RA+CCR7+CD25lo. Other
three SPADE branches represented distinct clusters of T cells expressing
CD25 and CCR6, co-expressing Lag-3, CTLA4 and GITR and were pre-
sent in both the TtolDC and TmDC lines.
To further dissect the composition of the TtolDC and TmDC lines, a
Hierarchical Stochastic Neighbor Embedding (HSNE) analysis was
performed. This novel dimensionality reduction technique im-
plemented in the Cytosplore platform[23–25], enabled the analysis of
our large data consisting of 1,016,321 cells without having to down
sample data by constructing a hierarchy which can be explored step-
wise up to the single-cell level. This strategy allows the efficient de-
tection of low frequent cell subsets[25]. A global view of data derived
from the TtolDC and TmDC lines is visualised in Fig. 4A. Three main
groups were formed using the Gaussian-mean-shift method and each
group was further inspected by zooming into the single-cell data level
(Fig. 4B). The three main groups were distinguished by the expression
of CD45RA, CCR7 and CD25; group A largely consisted of cells ex-
pressing CD45RA, CCR7 and low levels of CD25, group B of cells ne-
gative for CD45RA and low expression of CCR7 and CD25, and group C
of cells lacking CD45RA and CCR7 but expressing high levels of CD25.
Further clustering of these groups resulted in seven smaller clusters
within group A; seven clusters in group B and six clusters in group C.
The phenotypes of the generated clusters were visualised in a heatmap
(Fig. 4C) together with the number of cells per cluster originating from
the suppressive TtolDC line, non-suppressive TtolDC lines and TmDC lines
(Fig. 4C and Supplementary Table 1). The clusters in group A contained
T cells with a naïve phenotype (clusters A3-A7) and consisted mainly of
suppressive TtolDC cells, matching the SPADE analysis. This group was
further characterized by the high expression of CD7 and CD27. Cell
clusters A1 and A2 were distinct from the general phenotype of group
A, exemplified by the lack of CCR7 expression, demarcating a TEMRA
phenotype, of which one cluster (A1) specifically expressed CD161. The
clusters in group B displayed an effector memory (EM; CD45RA-CCR7-
CD25hi) phenotype, while group C displayed a central memory (CM;
CD45RA-CCR7loCD25lo) phenotype, consisting of cells derived from
both the TtolDC and the TmDC lines. However, TmDC lines contained more
EM cells than TtolDC lines, and these co-expressed HLA-DR, CD39, CD38
CD69, ICOS, CD45RO, CD28, PD-1 and CCR4. The clusters with a CM
phenotype were also more abundant in TmDC lines, with the exception
of two clusters (C4 and C5) co-expressing Lag-3 CTLA4 and GITR,
which largely contained TtolDC-originating cells. The signatures of TtolDC
and TmDC lines analysed separately in HSNE (Supplementary Fig. 2),
confirmed the presence of the specific clusters in TtolDC or TmDC lines.
Fig. 3. Multidimensional SPADE analysis of TtolDC and TmDC lines. TtolDC lines (green) show differential cluster distribution in the SPADE analysis from the TmDC
lines (red). The non-suppressive TtolDC line (blue) shows different distribution than the suppressive TtolDC lines. Circles depict clusters with designated marker
expression as shown in Supplementary Fig. 1. The grey arrow indicates the clusters lacking in the non-suppressive TtolDC line. (For interpretation of the references to
colour in this figure legend, the reader is referred to the Web version of this article.)
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In summary, using three independent methods to analyse the phe-
notype of TtolDC and TmDC cells, we show that T cell lines stimulated
with tolDCs acquire substantially different phenotypes than T cells
stimulated with mDCs. The abundant presence of
CD45RA+CCR7+CD25lo naïve T cells marked suppressive TtolDC lines,
while cells with CM and EM phenotypes were abundant in both TmDC
and TtolDC lines. Two TEMRA-like and two CM subsets were enriched in
the suppressive TtolDC lines.
(caption on next page)
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3.3. Suppressive capacity of TtolDC and TmDC subpopulations
To evaluate which of the three groups of cells in the TtolDC lines
defined by the multidimensional phenotypic analyses contains T cells
with suppressive capacity, cells from TtolDC and TmDC lines were sorted
based on the expression of CD45RA and CD25 and tested in a sup-
pression assay (Fig. 5). The CD45RA+ T cells (representing group A)
were only present in the suppressive TtolDC line but lacked suppressive
capacity. In contrast, both CD45RA-CD25hi and CD45RA-CD25lo T cells
(representing group C and B, respectively) sorted from TtolDC lines
showed suppressive capacity (Fig. 5B and C; one-way ANOVA p=0.03
and p= 0.04), whereas CD45RA-CD25hi and CD45RA-CD25lo T cells
derived from TmDC did not suppress allogeneic CD4+ T cell proliferation
(Fig. 5B and C).
Next, we evaluated whether TtolDC can inhibit target-cell killing by
autoreactive CD8+ T cells. For this, clonal preproinsulin (PPI)-specific
CD8+ T cells were incubated with PPI-peptide pulsed target cells in the
presence of total or sorted TtolDC populations. From the sorted TtolDC
Fig. 4. High dimensional analysis comparing TtolDC and TmDC lines. The CyTOF data of TtolDC and TmDC were analysed together using Hierarchical Stochastic
Neighbor Embedding (HSNE). HSNE integrates the information of 35 markers measured on a single cell level in a two-dimensional HSNE map. A) Groups A, B and C
depict three major landmarks in the HSNE overview level. Green areas depict cells originating from TtolDC, blue areas: cells from the non-suppressive TtolDC line, red
areas: cells from TmDC lines. B) tSNE plots of landmark groups A, B and C were visualised (at single-cell data level) with respect to expression of CD45RA, CCR7 and
CD25. Group A consists mainly of CD45RA+ cells, group B consists of CD45RA- and CD25lo cells and CD25hi cells were mainly found in group C. C) Heatmap of the
HSNE. Resulting clusters are visualised as rows in the heatmap. Cluster names refer to the originating group. Heatmap in the middle panel visualises the distribution
relative to the number of cells in a cluster. The right histogram shows the abundance of cells within the cluster in absolute numbers, taking into account the origin of
cells (green: TtolDC, blue: non-suppressive TtolDC line, red: TmDC). Statistics of the histogram are shown in Supplementary Table 1. The three pie-charts depict the
percentage of cells with a naïve, CM, EM or TEMRA phenotype within the TmDC, TtolDC and non-suppressive TtolDC lines. The clusters with a naïve-like phenotype
(CD45RA+CCR7+) were explicitly present in the TtolDC lines. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
Fig. 5. TtolDC with antigen experienced phenotype suppress naïve T cell proliferation. mDCs pulsed with proinsulin C19A3 were co-cultured TtolDC or TmDC in a
1:10 ratio. Thereafter, T cells were stained and sorted based on CD45RA and CD25 expression. The suppressive capacity of the sorted populations was assessed in a
suppression assay. A) Gating strategy of the cell sorting. B and C) Graphs and histograms depict proliferation of the CFSE-labelled allogeneic responder T cells in the
presence of sorted TtolDC (green) or sorted TmDC (red) subsets relative to the responder proliferation alone (grey). Sorted memory-like CD25hi and CD25lo, but not
naïve-like CD45RA+ cells from TtolDC lines suppressed naïve T cell proliferation (one-way ANOVA p=0.03 and p= 0.04). In contrast, sorted TmDC were not
suppressive, irrespective of CD25 expression. Graphs depict representative of 2 independent experiments using T cell lines from different donors with similar results.
(For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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subpopulations, memory CD45RA-CD25hi TtolDC were most capable of
inhibiting CD8+ T cell-induced killing (Fig. 6A; two-way ANOVA
p=0.017 and p=0.0058), while inhibition by CD45RA+ and
CD45RA-CD25lo TtolDC was insignificant compared to the total TtolDC.
The inhibiting capacity of the unsorted TtolDC line was likely limited,
since the inhibiting CD45RA-CD25hi subset represented a small pro-
portion of the total TtolDC (approximately 7%).
To further characterize the TtolDC subpopulations, activation-in-
duced Foxp3 expression was determined upon stimulation with proin-
sulin pulsed mDC. CD45RA-CD25hi and CD45RA-CD25lo TtolDC showed
high or intermediate expression of intracellular Foxp3, respectively,
while CD45RA+ TtolDC did not express Foxp3. Lastly, cytokines were
measured in the supernatant of TtolDC subpopulations after re-challenge
with proinsulin-pulsed mDC. Minor amounts of cytokines were detected
in the supernatant of total TtolDC (Fig. 6C), corresponding with the data
from unsorted TtolDC lines (Fig. 1C). The majority of cytokines produced
by TtolDC was derived from the CD45RA-CD25hi and CD45RA-CD25lo
populations, while cytokine production by CD45RA+ TtolDC was nearly
undetectable.
From this, we conclude that CD45RA+ TtolDC are non-activated,
Foxp3-negative T cells, while TtolDC with CD45RA-CD25hi and CD45RA-
CD25lo phenotypes contain activated T cells with regulating capacity.
4. Discussion
In this study, we extensively characterized the surface phenotypes
and function of T cells stimulated with proinsulin peptide-pulsed
tolDCs. Non-suppressive T cells were generated by tolDCs with an
aberrant phenotype, underscoring the critical importance of CD52 and
CD86 expression as quality control markers for tolDCs’ ability to induce
suppressive Tregs[29]. Combining high-dimensional phenotyping with
functional assays, we discovered that the presence of unresponsive,
Foxp3 negative T cells holding a naïve-like phenotype
(CD45RA+CCR7+) characterized suppressive T cell cultures induced by
tolDCs. The functional suppressive T cells in tolDC-stimulated cultures
lost CD45RA and obtained either CCR7+CD25lo central memory or
CCR7-CD25hi effector memory phenotypes. Both subsets were capable
of suppressing allogeneic CD4+ T cell proliferation, while the inhibition
of CD8+ T cell killing was unique for effector memory CD45RA-CD25hi
TtolDC. Contrary to IL-10-induced Tr1 [17,18], suppressive TtolDC did not
produce anti-inflammatory cytokines, supporting our earlier observa-
tion on strongly suppressive Treg clones [22], while blocking of IL-10
and TGF-b did not affect the suppressive activity of tolDC-induced Tregs
[8].
We propose that the naïve T cell population in TtolDC lines reflects
their arrest in activation and differentiation secondary to the con-
comitant induction of regulatory T cells. RNAseq analyses revealed
several genes upregulated in tolDCs that are associated with inhibition
Fig. 6. Memory-like TtolDC expressing CD25hi protect target cells from CD8-induced killing. TtolDC were stimulated overnight with proinsulin pulsed mDC.
Thereafter, TtolDC cells were sorted into 3 groups based on the expression of CD45RA and CD25 (CD45RA+, CD45RA-CD25lo and CD45RA-CD25hi). A) The ability to
inhibit CD8+ T cell-induced killing was tested using PPI-specific CD8+ T cell clone as effector and B cells loaded with PPI-peptide as target. Total TtolDC or sorted
subsets were incubated with CFSE-labelled target cells in a 2:1 ratio overnight. PPI-specific CD8+ T cells were added for 4 h, after which target cell counts were
measured and % specific cell lysis was calculated. Specific lysis in the condition without TtolDC were approximately 10% and 20% respectively, and were set to the
maximum (0% inhibition). Data are shown as mean % inhibition ± SD. From the TtolDC subpopulations, CD45RA-CD25hi TtolDC shows significant inhibition of CD8+
T cell induced killing compared to the unsorted TtolDC (two-way ANOVA; p=0.017 and p= 0.0058). B) Intracellular Foxp3 expression of TtolDC line and the sorted T
cell populations after overnight stimulation with proinsulin peptide-pulsed mDC. C) Cytokine production by total and sorted TtolDC after overnight stimulation with
proinsulin peptide-pulsed mDC.
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of cell activation[29]. Indeed, yields of TtolDC after two weeks of culture
rarely exceeded the number of plated naïve T cells at the start of the
culture. In addition, T cell cultures stimulated by tolDCs never formed
cell-clusters and retained the round morphology of inactive T cells (data
not shown), possibly reflecting specific gene expression modifying the
tolDC capacity to interact with cells and extracellular matrix[29].
Which inhibitory molecules on tolDC or soluble mediators determine
the lack of close contact with T cells including the underlying me-
chanisms remain to be investigated.
The mechanisms by which tolDC-induced Tregs modulate immune
responses in vivo can be diverse. Islet infiltrating lymphocytes rarely
contain Tregs in human T1D [31,32]. Instead, Tregs could protect beta
cells (lacking HLA class II) indirectly by modifying antigen specific cells
(APC) presenting proinsulin peptide in pancreas draining lymph nodes
which in turn inhibit effector T cells and protect pancreatic beta cells
[8]. Tregs may also induce bystander suppression of neighboring T cells
by scavenging for essential cytokines and nutrients. Indeed, effector
memory TtolDC in this study showed low IL-2 content in the supernatant
and inhibited islet autoreactive CD8+ T cells, while expressing more
Foxp3 than central memory TtolDC. This difference could be explained
by high expression of IL-2Rα (CD25), enabling this subset to capture
and deprive other cells from IL-2, a mechanism proven essential to limit
CD8+ T cell activation but not to control CD4+ T cell responses [33]. In
addition, the signaling by the captured IL-2 could support higher Foxp3
expression in this subset[34].
Using mass cytometry based analysis, the memory TtolDC popula-
tions were further subdivided into clusters characterized by expression
of previously described Treg markers such as HLA-DR [35], CD39 [36],
Lag-3 [37], CTLA4 [38], ICOS [39], CCR4 [40] and CD161 [41,42].
TtolDC with an effector memory phenotype co-expressed the markers
CD28, CD38, CD39, CCR4, HLA-DR, ICOS and PD-1. In our analysis, we
found a distinct population enriched in the TtolDC lines co-expressing
Lag-3, CTLA4 and GITR within the central memory and naïve pheno-
type. In addition, a small population characterized by CD161 was found
within the TEMRA phenotype suggesting that T cells with TEMRA phe-
notype contain adaptive Tregs. This concurs with reports suggesting
that TEMRA are not merely unresponsive, exhausted cells[43]. In view of
their low frequency however, it is unlikely that only CD161+ cells
contribute to the suppressive activity of the CD25hi subset. Based on our
findings here and our previous work[8], we presume that different T
cell subsets such as CD161+ and Lag-3+ T cells contribute to the sup-
pressive capacity of tolDC-induced Tregs.
The complexity and diversity of circulating nTregs has been de-
scribed using mass cytometry and resembles the phenotypical signature
that we report here on the tolDC-stimulated T cell lines, as well as those
we reported previously [21,22]. nTregs, too, can be subdivided into
several populations expressing CD45RO, CCR4, HLA-DR, ICOS, CD38,
CD39 and a distinct CD161+ population. Although this would suggest
that induced antigen-specific Tregs look similar to Foxp3+ nTregs, our
studies show that most of these markers can also be present on acti-
vated non-suppressive T cells. Furthermore, we demonstrated that
tolDCs also induce antigen-specific Tregs with CD25lo and Foxp3dim
phenotype. Additional markers are therefore needed to identify induced
suppressive cells in peripheral blood following immune modifying
therapies. Subpopulations with unique suppressive qualities were
identified, prompting follow-up analyses using an extended list of
suppression-associated surface and intracellular molecules. The reg-
ulatory phenotypes described here may provide viable biomarkers of
immune regulation in the clinic, enabling detection of induced Tregs
after tolDC administration in vivo.
5. Conclusions
In summary, multiparameter analysis revealed phenotypical sig-
natures of tolDC-stimulated T cells and showed that tolDC-induced
Tregs obtain differential phenotypes, which corresponds to earlier
findings of Treg diversity. We additionally demonstrate that partial
tolerogenic modulation of DCs reflects in an atypical tolDC phenotype
and reduced the Treg-inducing capacity. Suppressive T cells induced by
tolDCs acquire different memory phenotypes, including cells expressing
Lag-3, CD161 and ICOS. These markers, however, are also expressed by
non-suppressive T cells. TolDC-induced T cell lines also retain or fix
naïve-like T cells in a non-activated and non-suppressive state. This,
however, mirrors the induction of suppressive activity. Our combined
findings in vitro provide a basis for monitoring and optimization of the
clinical use of tolDC therapies.
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